GLP-1 News for 2026: New Regulations for Compounded Semaglutides

Here’s what you need to know up front: Running a medical weight loss program with GLP-1 medications in 2026 requires close attention to new regulations, FDA enforcement, and sourcing rules. Clinics need a documented process for purchase decisions, supplier approval, and order records.

Demand has made vendor oversight a larger operational responsibility. This industry analysis of GLP-1 demand and medical aesthetics provides market context. Clinics should verify whether a product can be lawfully supplied, whether the seller is licensed, and whether the documentation will stand up to review.

This guide covers the biggest GLP-1 compliance changes for 2026 and what to update across supplier approval, purchasing, inventory, records, and marketing.

What's New for Med Spas Running GLP-1 Programs in 2026?

The compounded semaglutide sourcing environment has changed significantly since the drug-shortage period. During the shortage, compounders had more flexibility under federal policy. That flexibility has narrowed, so purchasing practices created during the shortage need to be reviewed against current federal and state requirements.

Why Clinics Turned to Compounded Semaglutide

When Ozempic and Wegovy were difficult to obtain, compounding pharmacies became an additional source. By 2025, the U.S. weight loss market hit $135 billion, and around 60% of med spas offered GLP-1 programs. Clinics should inventory sources adopted during that period, identify each 503A pharmacy or 503B outsourcing facility, and document the basis for continuing orders.

Here’s What’s Changed in 2026

On February 21, 2025, the FDA said the semaglutide shortage was over. That changed the federal conditions for compounding copies of commercially available semaglutide products. By spring, the shortage-related enforcement discretion periods had ended.

The FDA sent 30 warning letters to telehealth companies in March alone, and by the end of April, it proposed taking semaglutide, tirzepatide, and liraglutide off the 503B Bulk Drug Substances List altogether.

This is not only a pharmacy issue. The rules affect intake documentation, marketing review, purchase authorization, receiving procedures, inventory reconciliation, and the language staff use when identifying FDA-approved and compounded products.

Understanding Compounded Semaglutide Rules

Compounded semaglutide is not an FDA-approved drug and is not reviewed through the FDA new drug approval process. Verify approval status, compounding authority, source identity, and patient-specific documentation separately before purchase.

Shortage Status and When Rules Changed

An official FDA shortage can permit certain compounding activity. That room narrows when the shortage ends. The shortage ended in February 2025. Flexibility for 503A pharmacies ended April 22, 2025. For 503B outsourcing facilities, it ended May 22, 2025. Check FDA resources and state requirements, and have counsel review any claimed exception.

The Difference Between 503A and 503B Facilities

• 503A pharmacies are state licensed and generally compound for patient-specific prescriptions. Verify active licenses, the prescriber relationship, and required prescription records.
• 503B outsourcing facilities register with the FDA and may produce office stock under applicable conditions. Confirm registration, inspection history, product eligibility, shipping states, and lot records.

"Essentially a Copy" Issues

Lower price or easier access does not establish a lawful basis for buying compounded semaglutide. Regulators scrutinize products that are essentially copies of commercially available FDA-approved drugs without an exception. Get the supplier’s legal basis in writing, retain it, and have counsel review it before recurring purchases.

Semaglutide Salts and Drug Quality

The FDA has warned about semaglutide sodium and semaglutide acetate. These forms are not the same active ingredient used in FDA-approved semaglutide products, and the FDA has said it is not aware of a lawful basis for their use in compounding.

Confirm the precise ingredient form before purchase. Obtain certificates of analysis, lot-specific testing records, shipping documentation, and the supplier’s current licenses. As of July 2025, the FDA had received 605 adverse event reports tied to compounded semaglutide. Clinics should know how the supplier receives, investigates, and reports product complaints and adverse events.

How These Changes Affect Your Med Spa’s Weight Loss Program

Compliance responsibilities reach across the clinic. Review:

• How product names and approval status appear in patient-facing materials
• How supplier eligibility and state licenses are verified
• How purchase decisions and prescriptions are documented
• How products are ordered, received, stored, and tracked
• How staff explain product identity without making unsupported comparisons

Patient Leads and Advertising

The FDA’s 2026 warning letters targeted clinics and telehealth companies for unsupported comparisons between compounded and branded products. Audit websites, ads, booking pages, email, SMS, and staff scripts, and remove or correct those comparisons.

Identify whether a product is FDA-approved or compounded in plain language. Do not imply that a compounded preparation is approved, equivalent to a branded drug, or reviewed under the same process. Route product-specific clinical questions to appropriately licensed clinical staff.

Medical Intake and Screening

GLP-1 prescribing is medical care. Operations staff should confirm that each file includes:

• The patient’s identity and state location at the time of service
• The treating clinician’s identity, credentials, and state license
• The prescribed product’s exact name and FDA approval status
• The dispensing pharmacy, prescription, and order identifiers
• Signed informed-consent and required disclosure records

State boards may review when documentation was completed. The medical director and counsel should define requirements, while operations staff audit completeness.

Monitoring and Adverse Events

Document who receives product complaints, contacts the pharmacy or manufacturer, records the information, and handles federal or state reporting. Keep supplier contacts current and test the escalation path.

• Record the product name, source, lot number, and expiration date
• Preserve relevant order, receipt, storage, and temperature records
• Document the date, responsible staff member, escalation, and supplier response

Keep affected packaging and records until review closes. Document quarantine, return, recall, replacement, or credit so inventory and financial records align.

Ordering, Inventory, and Chain of Custody

Stop informal ordering. Keep clear records for every product, including:

• Source and dispensing or outsourcing facility
• Lot number
• Expiration date
• Required and recorded storage conditions
• The patient-specific or office-stock record that authorizes possession

For 503A orders, confirm the patient-specific prescription requirement first. Reconcile orders, shipping records, quantities, storage logs, and disposition. Quarantine shipments with broken seals, missing lot data, temperature excursions, or labeling changes.

GLP-1 Compliance Checklist for Clinic Owners

Use this as an operations audit list. It is not legal advice. Work with healthcare counsel, your medical director, pharmacy partners, and the relevant state boards, and document the date and source of every regulatory check.

Check All Your Suppliers

• Verify active licenses directly with the issuing authority
• Confirm 503A or 503B status and what that status permits
• Check FDA registration when applicable
• Review state pharmacy board status, discipline, and shipping authority
• Obtain certificates of analysis and lot records for every product
• Understand complaint, recall, return, and adverse-event reporting processes

Review Your Prescribing

• Verify prescriber credentials and scope of practice
• Document medical director oversight responsibilities
• Confirm telehealth providers are licensed in the patient’s state during visits
• Map state telemedicine and prescribing rules to your workflow
• Require the clinician to document the legal and clinical basis for each prescription

Review state licensure requirements for telehealth visits and maintain evidence that each provider was authorized to practice where the patient was located.

Update Informed Consent and Education

• State clearly whether the product is FDA-approved or compounded
• Use clinician-approved materials that accurately identify known risks
• Explain clinic contact and follow-up procedures without promising an outcome
• Provide clear instructions for reporting a product problem
• Have counsel or a qualified compliance expert review the language

Audit Website, Ads, and Social

• Check every channel, including website, ads, email, SMS, and booking pages
• Remove language that calls compounded products FDA-approved, generic, identical, or equivalent to branded products
• Remove efficacy, therapeutic, dosing, and outcome claims for compounded GLP-1 products

Train Front Desk and Patient Coordinators

• Give non-clinical staff approved scripts for product identity, pricing, scheduling, and routing questions
• Send clinical, eligibility, dosing, safety, and outcome questions to licensed clinical staff

Business Risks if You Ignore These Rules

Weak sourcing and documentation can create several operational and regulatory problems:

• Product supply interruptions
• Patient, pharmacy-board, or medical-board complaints
• Advertising disapprovals or account restrictions
• Corrective-action costs and reputation damage
• Unreconciled inventory, refunds, disputes, or chargebacks
• Telehealth compliance failures can create serious licensure and enforcement exposure

A missing license check, unsupported product comparison, or incomplete chain-of-custody record can affect relationships with patients, regulators, payment providers, and suppliers.

Margins Under Pressure

A business model that depends on low-cost compounded products is exposed to rule changes, supplier interruptions, replacement purchases, shipping costs, spoilage, and credits. Track acquisition cost, freight, cold-chain packaging, storage, waste, returns, and rebates separately. Maintain more than one vetted source where lawful, without bypassing existing representative relationships or supplier controls.

Building Patient Trust and Continual Care

Patient-facing records should accurately identify the prescribed product, approval status, dispensing source, and clinic contact process. Use consistent language across consent forms, invoices, packaging handoffs, portals, and staff scripts. If a source or product changes, update those materials and preserve the earlier version for the audit trail.

Operational Roadblocks as You Grow

Spreadsheets and sticky notes make it difficult to connect licenses, purchase approvals, lot numbers, storage logs, patient-specific records, returns, and recalls. As order volume grows, use controlled access, required fields, exception alerts, and regular reconciliation. Assign an owner for supplier files and another reviewer for periodic checks.

How to Build a Defensible GLP-1 Program

A defensible program connects clinical governance with supplier approval, purchasing controls, inventory records, marketing review, and documented staff responsibilities.

Standardize Clinical Protocols

• Document required intake, consent, and prescription records
• Set rules for purchase authorization, receipt, storage, and refills
• Define how staff handle shortages, substitutions, recalls, and product complaints
• Have the medical director approve clinical materials and escalation responsibilities
• Version and update the protocol when regulations or suppliers change

Keep Clinical Decisions Away from Marketing Pressure

Purchasing targets, promotional calendars, rebates, and inventory levels should not control individual prescribing decisions. Separate marketing approval, procurement approval, and clinical authorization in the workflow. Keep an audit trail showing who made each decision and which current policy or record supported it.

Let Your EHR Help with Compliance

Choose an EHR and inventory setup that can support required records and make exceptions visible. Look for:

• Chart templates with required product and source fields
• Version-controlled consent forms
• Task and documentation reminders
• Secure patient messages
• Inventory, lot, expiration, and disposition tracking
• Customizable audit and purchasing reports

A connected medical weight loss workflow can reduce missing records and duplicate entry. Confirm that your software fits your medical director’s requirements, state rules, pharmacy workflow, and inventory process.

Be Ready for New Products

There are now more FDA-approved oral GLP-1 products. Oral Wegovy was approved in December 2025, and oral orforglipron, branded Foundayo, in April 2026. Before adding a product, update formulary records, manufacturer and distributor files, storage requirements, ordering permissions, staff references, patient materials, and billing entries. Avoid substituting a compounded product based only on name, format, availability, or price.

How Portrait Helps You Save and Run Smoother

Supply costs need active management. Portrait’s Marketplace helps med spa owners compare and order wellness and medical weight loss supplies, with savings of up to 60% on select products. Some savings are reflected at purchase, while qualifying rebates may apply to future orders. Review product details, supplier terms, shipping charges, storage requirements, and rebate conditions before authorizing an order.

Portrait’s Marketplace brings ordering, inventory reminders, and spend tracking into one place. It is additive to existing representative relationships and does not require a clinic to replace them. Portrait also provides EHR, scheduling, payment, compliance tools, MD matching, Good Faith Exam features, and marketing support. Review Portrait’s GLP-1 operations guide for additional workflow context. Clinics should still verify product status, supplier licensing, state requirements, and internal approvals for each purchase. Learn more at portraitcare.com .

Keep Your Clinic Ready for What’s Next

In 2026, GLP-1 program operations require regular review. FDA enforcement, state oversight, shortage status, and compounding rules can change what a clinic may source and how it must document each transaction. Set a review calendar for supplier licenses, FDA records, contracts, certificates, marketing language, inventory controls, and staff training.

Work with qualified legal and clinical advisors, verify suppliers at the source, and use systems that provide a complete purchasing and documentation trail. A clear process helps the clinic respond to inspections, recalls, supplier changes, and cost shifts. For operational support with your GLP-1 program and more, contact Portrait for an intro call.

Related reading

• 503A vs 503B Pharmacy: What Your Practice Can Stock
• Who Can Buy Botox? Licensing Guide for Practices
• Compounded Tirzepatide 2026 - FDA Rule Change Guide
• Medical Spa Laws and Requirements in Oklahoma
• Medical Spa Laws and Requirements in Utah